NasdaqGS - Nasdaq Real Time Price USD
Dyne Therapeutics, Inc. (DYN)
9.40
-0.62
(-6.19%)
At close: May 7 at 4:00:00 PM EDT
8.70
-0.70
(-7.45%)
Pre-Market: 4:03:53 AM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John G. Cox M.B.A. | CEO, President & Director | 1.03M | -- | 1963 |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Innovation Officer | 719.52k | 2.17M | 1961 |
| Ms. Johanna Friedl-Naderer | Chief Commercial Officer | 748.77k | -- | 1968 |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer | 745.64k | -- | 1968 |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Officer | -- | -- | 1967 |
| Mr. James P. Bilotta M.B.A. | Chief Digital & Information Officer | -- | -- | -- |
| Dr. Ranjan Batra Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Daniel Wilson | Senior VP & Head of Legal | -- | -- | 1972 |
| Ms. Lucia Celona | Chief Human Resource Officer | -- | -- | 1966 |
| Ms. Debra Feldman | Chief Regulatory Affairs Officer | -- | -- | 1971 |
Dyne Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 191
Description
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 8, 2025 at 8:00 PM UTC - May 15, 2025 at 8:00 PM UTC
Dyne Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
RNA Avidity Biosciences, Inc.
26.17
-0.34%
EWTX Edgewise Therapeutics, Inc.
14.52
+0.97%
TRDA Entrada Therapeutics, Inc.
8.16
-2.04%
IMVT Immunovant, Inc.
13.88
+0.29%
SLDB Solid Biosciences Inc.
2.5900
-23.15%
STOK Stoke Therapeutics, Inc.
8.66
-1.03%
VERA Vera Therapeutics, Inc.
22.62
+2.77%
DNLI Denali Therapeutics Inc.
14.32
+2.51%
WVE Wave Life Sciences Ltd.
6.49
+1.25%
SION Sionna Therapeutics, Inc.
12.88
+0.94%